The 2nd international drug hypersensitivity meeting

Expert Opinion on Drug Safety

Volumn 5, Issue 5, 2006, Pages 729-734

  Alfirevic, Ana ^a   Naisbitt, Dean J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Drug hypersensitivity; Drug metabolism; Immunogenetics; Predictive test; T cell

Indexed keywords

ABACAVIR; ANESTHETIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CONTRAST MEDIUM; HLA B ANTIGEN; NEVIRAPINE; SULFAMETHOXAZOLE;

ALLERGY; ANAPHYLAXIS; CELL FUNCTION; CHEMISTRY; CLINICAL CHEMISTRY; CLINICAL PHARMACOLOGY; CONFERENCE PAPER; DESENSITIZATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; HUMAN; IMMUNOGENETICS; IMMUNOLOGY; MEDICAL EXPERT; MEDICAL RESEARCH; MOLECULAR DYNAMICS; NONHUMAN; PHARMACOGENETICS; STEVENS JOHNSON SYNDROME; SYMPOSIUM; TOXIC EPIDERMAL NECROLYSIS; TOXICOLOGY; UNITED KINGDOM; VIRUS REACTIVATION; ARTICLE; CLINICAL TRIAL; EXPERT WITNESS; ORGANIZATION; STANDARD;

CLINICAL TRIALS; CONGRESSES; DRUG HYPERSENSITIVITY; EXPERT TESTIMONY; GREAT BRITAIN; HUMANS;

EID: 33747505420     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.5.729     Document Type: Conference Paper

References (27)

1. MERTES PM, LAXENAIRE MC: [Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France. Seventh epidemiologic survey (January 2001-December 2002)]. Ann. Fr. Anesth. Reanim. (2004) 23:1133-1143.
2. LAXENAIRE MC, MERTES PM: Anaphylaxis during anaesthesia. Results of a two-year survey in France. Br. J. Anaesth. (2001) 87:549-558.
3. MERTES PM, LAXENAIRE MC, LIENHART A et al.: Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice. J. Investig. Allergol. Clin. Immunol. (2005) 15:91-101.
4. ROUJEAU JC: Clinical heterogeneity of drug hypersensitivity. Toxicology (2005) 209:123-129.
5. PICHLER WJ: Delayed drug hypersensitivity reactions. Ann. Intern. Med. (2003) 139:683-693.
6. BACHOT N, ROUJEAU JC: Differential diagnosis of severe cutaneous drug eruptions. Am. J. Clin. Dermatol. (2003) 4:561-572.
7. AFTER AJ, KINMAN JL, BILKER WB et al.: Represcription of penicillin after allergic-like events. J. Allergy Clin. Immunol. (2004) 113:764-770.
8. MESSAAD D, SAHLA H, BENAHMED S, GODARD P, BOUSQUET J, DEMOLY P: Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann. Intern. Med. (2004) 140:1001-1006.
9. DEMOLY P, KROPF R, BIRCHER A, PICHLER WJ: Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. Allergy (1999) 54:999-1003.
10. BROCKOW K, ROMANO A, BLANCA M, RING J, PICHLER W, DEMOLY P: General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy (2002) 57:45-51.
11. ABERER W, BIRCHER A, ROMANO A et al.: Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy (2003) 58:854-863.
12. TORRES MJ, BLANCA M, FERNANDEZ J et al.: Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy (2003) 58:961-972.
13. ROMANO A, BLANCA M, TORRES MJ et al.: Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy (2004) 59:1153-1160.
14. BROCKOW K, CHRISTIANSEN C, KANNY G et al.: Management of hypersensitivity reactions to iodinated contrast media. Allergy (2005) 60:150-158.
15. DELRIEU O, BOWMAN C: Visualizing gene determinants of disease in drug discovery. Pharmacogenomics (2006) 7:311-329.
16. MALLAL S, NOLAN D, WITT C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet (2002) 359:727-732.
17. HETHERINGTON S, HUGHES AR, MOSTELLER M et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet (2002) 359:1121-1122.
18. HUGHES DA, VILAR FJ, WARD CC, ALFIREVIC A, PARK BK, PIRMOHAMED M: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics (2004) 14:335-342.
19. CHUNG WH, HUNG SI, HONG HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature (2004) 428:486.
20. LONJOU C, THOMAS L, BOROT N et al.: A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. (2006) 6:265-268.
21. CUMBERBATCH M, CLELLAND K, DEARMAN RJ, KIMBER I: Impact of cutaneous IL-10 on resident epidermal Langerhans' cells and the development of polarized immune responses. J. Immunol. (2005) 175:43-50.
22. + T cells are efector cells of contact dermatitis to common skin allergens in mice. J. Invest. Dermatol. (2006) 126:815-820.
23. + regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J. Immunol. (2003) 171:5760-5768.
24. PICHLER WJ: Delayed drug hypersensitivity reactions. Ann. Intern. Med. (2003) 139:683-693.
25. DEPTA JP, ALTZNAUER F, GAMERDINGER K, BURKHART C, WELTZIEN HU, PICHLER WJ: Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. J. Allergy Clin. Immunol. (2004) 113:519-527.
26. SCHMID DA, DEPTA JP, LUTHI M, PICHLER WJ: Transfecrion of drug-specific T-cell receptors into hybridoma cells: tools to monitor drug interaction with T-cell receptors and evaluate cross-reactivity to related compounds. Mol. Pharmacol. (2006) 70:356-365.
27. SHENTON JM, POPOVIC M, CHEN J, MASSON MJ, UETRECHT JP: Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem. Res. Toxicol. (2005) 18:1799-1813.